X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (505) 505
mgus (470) 470
index medicus (379) 379
multiple myeloma (346) 346
monoclonal gammopathy (292) 292
hematology (281) 281
male (264) 264
female (261) 261
middle aged (259) 259
aged (246) 246
oncology (213) 213
multiple-myeloma (170) 170
undetermined significance mgus (166) 166
adult (164) 164
prognosis (138) 138
monoclonal gammopathy of undetermined significance (134) 134
aged, 80 and over (129) 129
undetermined significance (126) 126
disease progression (115) 115
progression (111) 111
risk (111) 111
multiple myeloma - diagnosis (105) 105
myeloma (105) 105
diagnosis (94) 94
risk factors (93) 93
multiple myeloma - pathology (92) 92
prevalence (92) 92
multiple myeloma - genetics (89) 89
cancer (81) 81
monoclonal gammopathy of undetermined significance - diagnosis (76) 76
long-term (72) 72
hemic and lymphatic diseases (70) 70
significance mgus (68) 68
medicine, general & internal (63) 63
article (60) 60
multiple myeloma - therapy (53) 53
gammopathy (52) 52
survival (52) 52
monoclonal gammopathy of undetermined significance - complications (51) 51
paraproteinemias - diagnosis (51) 51
amyloidosis (48) 48
care and treatment (48) 48
monoclonal gammopathy of undetermined significance - pathology (48) 48
multiple myeloma - etiology (48) 48
abridged index medicus (47) 47
disease (47) 47
multiple myeloma - immunology (47) 47
bone marrow (46) 46
retrospective studies (46) 46
monoclonal gammopathy of undetermined significance - epidemiology (44) 44
research (44) 44
follow-up (43) 43
follow-up studies (43) 43
immune system diseases (42) 42
hematology, oncology and palliative medicine (41) 41
stem-cell transplantation (41) 41
medicine & public health (40) 40
pathology (40) 40
plasma-cells (40) 40
therapy (40) 40
bone marrow - pathology (39) 39
paraproteinemias - complications (39) 39
multiple myeloma - blood (37) 37
analysis (36) 36
expression (36) 36
monoclonal gammopathies (36) 36
paraproteinemias - immunology (36) 36
smoldering multiple-myeloma (35) 35
treatment outcome (35) 35
monoclonal gammopathy of undetermined significance - blood (34) 34
young adult (34) 34
development and progression (33) 33
diagnosis, differential (33) 33
multiple myeloma - drug therapy (33) 33
multiple myeloma - mortality (33) 33
paraproteinemias - pathology (33) 33
peripheral neuropathy (33) 33
plasma cells - pathology (33) 33
case-control studies (32) 32
management (32) 32
monoclonal gammopathy of undetermined significance - genetics (32) 32
multiple myeloma - epidemiology (32) 32
immunoglobulins (31) 31
plasma cells (31) 31
transplantation (31) 31
immunology (30) 30
monoclonal gammopathy of undetermined significance - immunology (30) 30
neuropathy (30) 30
paraproteinemias - blood (30) 30
united-states (30) 30
flow cytometry (29) 29
multiple myeloma - metabolism (29) 29
biopsy (28) 28
bone-marrow (28) 28
clinical neurology (28) 28
disorders (28) 28
epidemiology (27) 27
light-chain ratio (27) 27
malignant-transformation (27) 27
monoclonal gammopathy of undetermined significance - etiology (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (717) 717
French (29) 29
German (24) 24
Japanese (9) 9
Spanish (9) 9
Czech (5) 5
Polish (5) 5
Italian (4) 4
Korean (3) 3
Slovak (2) 2
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neurology, ISSN 0028-3878, 07/2019, Volume 93, Issue 3, pp. e298 - e305
OBJECTIVETo describe the clinical phenotype, long-term treatment outcome, and overall survival of sporadic late-onset nemaline myopathy (SLONM) with or without... 
MGUS | CLINICAL NEUROLOGY | TRANSPLANTATION
Journal Article
Revue medicale de Bruxelles, ISSN 0035-3639, 09/2018, Volume 39, Issue 4, pp. 302 - 306
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2019, Volume 186, Issue 5, pp. 653 - 654
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2019
Journal Article
Muscle & Nerve, ISSN 0148-639X, 06/2016, Volume 53, Issue 6, pp. 856 - 861
ABSTRACT Introduction: The etiology of neuropathy was idiopathic in 20%–30% of patients despite thorough investigation, based on results from the 1980s and... 
neuropathy | MGUS | idiopathic | CIDP | diabetes | prediabetes
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 676 - 681
Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias, which... 
Health disparity | MGUS | Smoldering myeloma | Epidemiology | Multiple myeloma | CRITERIA | POPULATION | PROGNOSIS | LONG-TERM SURVIVAL | NATIONAL-HEALTH | RACIAL DISPARITIES | YOUNGER | ONCOLOGY | MONOCLONAL GAMMOPATHY | UNDETERMINED SIGNIFICANCE MGUS | Multiple Myeloma - epidemiology | Multiple Myeloma - therapy | Time Factors | Multiple Myeloma - mortality | Humans | Middle Aged | Aged, 80 and over | Adult | Aged
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2009, Volume 144, Issue 5, pp. 686 - 695
Summary Increased levels of naturally occurring regulatory T cells (TReg cells) have been found in a variety of solid tumours and haematological malignancies.... 
regulatory T cells | Double Negative T cells | myeloma | Foxp3 | MGUS | Myeloma | Regulatory T cells
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 04/2019, Volume 46, Issue 2, pp. 112 - 120
Currently the standard of care for smoldering multiple myeloma (SMM) is "watch and wait." However, in recent years the treatment for multiple myeloma (MM) has... 
MULTIPLE-MYELOMA | LONG-TERM | DEXAMETHASONE | Lenalidomide | ABNORMALITIES | Smoldering multiple myeloma | RISK | THALIDOMIDE | Asymptomatic multiple myeloma | Treatment | THERAPY | ONCOLOGY | Plasma cell disorders | Carfilzomib | MONOCLONAL GAMMOPATHY | MGUS | PROGRESSION | UNDETERMINED SIGNIFICANCE MGUS
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 11/2018, Volume 59, Issue 11, pp. 2660 - 2669
Oncogene-induced senescence (OIS) is a cellular tumor-suppressive mechanism present in several premalignant conditions. Here, we analyze the possible impact of... 
senescence | tumor suppression | multiple myeloma | MGUS | Hematological malignancy | MULTIPLE-MYELOMA | LONG-TERM | ABNORMALITIES | TRIGGERS | PROLIFERATION | ARREST | ONCOLOGY | INHIBITOR P27 | MONOCLONAL GAMMOPATHY | HEMATOLOGY | P27(KIP1) EXPRESSION | UNDETERMINED SIGNIFICANCE MGUS
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
La Revue de Médecine Interne, ISSN 0248-8663, 08/2019
Journal Article
by Go, RS
BRITISH JOURNAL OF HAEMATOLOGY, ISSN 0007-1048, 05/2010, Volume 149, Issue 4, pp. 620 - 621
Journal Article